Crossmark

Effectiveness and safety of alirocumab and evolocumab for hypercholesterolemia in a population with high cardiovascular risk

Crossref DOI link: https://doi.org/10.1016/j.medcle.2024.05.007

Published Print: 2024-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Bosch, Montserrat

Danés, Immaculada

Ballarín, Elena

Marrero, Patricia

Vancells, Guillem

Ortiz-Zúñiga, Ángel

Urquizu-Padilla, Maria

Rial-Lorenzo, Nuria

Lozano-Torres, Jordi

Rodríguez-Luna, David

Filippi-Arriaga, Francesca

Agustí, Antònia
License Information

Text and Data Mining valid from 2024-10-01

Text and Data Mining valid from 2024-10-01

stm-asf valid from 2024-10-01

stm-asf valid from 2024-10-01

stm-asf valid from 2024-10-01

stm-asf valid from 2024-10-01

stm-asf valid from 2024-10-01
More Information

This article is maintained by: Elsevier

Article Title: Effectiveness and safety of alirocumab and evolocumab for hypercholesterolemia in a population with high cardiovascular risk

Journal Title: Medicina Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcle.2024.05.007

Content Type: article

Copyright: © 2024 Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.